Immunotherapy in psoriasis

被引：9

作者：

Landeck, Lilla ^{[1
]}

Sabat, Robert ^{[2
]}

Ghoreschi, Kamran ^{[3
]}

Man, Xiao-Yong ^{[4
]}

Fuhrmeister, Katja

Gonzalez-Martinez, Ernesto ^{[5
]}

Asadullah, Khusru ^{[3
]}

机构：

[1] Ernst von Bergmann Gen Hosp, Dept Dermatol, D-14467 Potsdam, Germany

[2] Charite Univ Med Berlin, Psoriasis Res & Treatment Ctr, Berlin, Germany

[3] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Berlin, Germany

[4] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Dermatol & Venereol, Hangzhou, Zhejiang, Peoples R China

[5] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 07期

关键词：

biologicals; COVID-19; cytokines; drug selection; drug targets; immunomodulation; individualized therapy; interleukins; pharmacology; skin inflammation; QUALITY-OF-LIFE; DIFFERENTIAL DRUG SURVIVAL; TUMOR-NECROSIS-FACTOR; OBSERVATIONAL COHORT; BRITISH ASSOCIATION; BIOLOGIC THERAPIES; SKIN; CYTOKINE; IL-22; RISK;

D O I：

10.2217/imt-2020-0292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Over the past two decades, a huge progress in the treatment of psoriasis was achieved by targeting the human cytokine network. At present, 11 biologicals - antibodies, and a soluble receptor - are used to neutralize key inflammatory cytokines. Based on their targets, they can be grouped into the following four classes: TNF-alpha-, IL-12/23-, IL-17- and IL-23-inhibitors. The number of substances, but also the different modes of action may be challenging, when selecting the right drug for an individual patient. In this article, we provide an overview of the available biologicals in the treatment of psoriasis, including their advantages and limitations, and summarize criteria for therapy selection.

引用

页码：605 / 620

页数：16

共 87 条

[61] Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer [J].

Porter, Charlene ;

Armstrong-Fisher, Sylvia ;

Kopotsha, Tim ;

Smith, Bryan ;

Baker, Terry ;

Kevorkian, Lara ;

Nesbitt, Andrew .

JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2016, 116 :7-12

[62] Biosimilars for the treatment of psoriasis [J].

Puig, Lluis ;

Lopez-Ferrer, Anna .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) :993-1000

[63] Psoriasis and infection. A clinical practice narrative [J].

Rademaker, Marius ;

Agnew, Karen ;

Anagnostou, Nicholas ;

Andrews, Megan ;

Armour, Katherine ;

Baker, Christopher ;

Foley, Peter ;

Gebauer, Kurt ;

Gupta, Monisha ;

Marshman, Gillian ;

Rubel, Diana ;

Sullivan, John ;

Wong, Li-Chuen .

AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 (02) :91-98

[64] Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial [J].

Reich, Kristian ;

Armstrong, April W. ;

Langley, Richard G. ;

Flavin, Susan ;

Randazzo, Bruce ;

Li, Shu ;

Hsu, Ming-Chun ;

Branigan, Patrick ;

Blauvelt, Andrew .

LANCET, 2019, 394 (10201) :831-839

[65] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial [J].

Reich, Kristian ;

Armstrong, April W. ;

Foley, Peter ;

Song, Michael ;

Wasfi, Yasmine ;

Randazzo, Bruce ;

Li, Shu ;

Shen, Y. -K. ;

Gordon, Kenneth B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :418-431

[66] T cell pathology in skin inflammation [J].

Sabat, Robert ;

Wolk, Kerstin ;

Loyal, Lucie ;

Doecke, Wolf-Dietrich ;

Ghoreschi, Kamran .

SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (03) :359-377

[67] Therapeutic opportunities of the IL-22-IL-22R1 system [J].

Sabat, Robert ;

Ouyang, Wenjun ;

Wolk, Kerstin .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (01) :21-38

[68] Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids [J].

Saghazadeh, Amene ;

Rezaei, Nima .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84

[69] Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response [J].

Sawyer, Laura M. ;

Malottki, Kinga ;

Sabry-Grant, Celia ;

Yasmeen, Najeeda ;

Wright, Emily ;

Sohrt, Anne ;

Borg, Emma ;

Warren, Richard B. .

PLOS ONE, 2019, 14 (08)

[70] Pathogenesis of psoriasis [J].

Schaekel, K. ;

Schoen, M. P. ;

Ghoreschi, K. .

HAUTARZT, 2016, 67 (06) :422-+

← 1 2 3 4 5 6 7 8 9 →